"We are pleased with the efficient manner in which the 18 clinical centers have enrolled patients in the phase II study," said Dr. Ming Chu Hsu, Chairman and CEO of TaiGen. "Completing enrollment in this study shall keep us on track of our projected development timeline for this highly promising antibacterial for the treatments of resistant infection."
About TaiGen Biotechnology Co., LTD
TaiGen Biotechnology (www.taigenbiotech.com ) is a leading pharmaceutical company based in Taiwan and has a wholly-owned subsidiary in Beijing, China. The company is developing novel therapeutics to treat infectious diseases, diabetic complications and cancer for the worldwide market. TaiGen has a full capacity in new drug R&D and clinical development in China, Taiwan, US and other countries. Nemonoxacin, an once-a-day oral and IV antibacterial active against gram-positive and -negative pathogens and MRSA, will soon to enroll diabetic foot infection patients in a double-blind phase 2 trial. The company has first-in-class phase 1-ready drug candidates for treating critical limb ischemia and retinopathy/age-related macular degeneracy, and advanced preclinical candidates for chronic Hepatitis C virus infection and cancer.
Contact Information: Stephen Ip, Ph.D. SVP Global Business Development Tel: +886-2-2790-1861 Fax: +8862-2790-9962 Email: sip@taigenbiotech.com Add: 7F, 138 Shin Ming Rd., Neihu Dist., Taipei, Taiwan 11470, R.O.C.
Source: TaiGen Biotechnology Co., LTD
